About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone is marketed by InterMune in the United States, EU and Canada as Esbriet®. Pirfenidone was approved for marketing in the United States on October 15, 2014. InterMune’s research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

On September 29, 2014, InterMune became a wholly owned subsidiary of Roche.

You are now leaving the InterMune website. If you would like to continue, click Continue. Otherwise, click Cancel.